References Sinha, R., et al
Which means it is possible, in principle, to design molecules that produce the parts of the GLP-1 effect that you want (appetite suppression, glycemic control, cardiovascular benefit) while minimizing the parts that you do not (gastrointestinal misery, certain forms of receptor downregulation, possibly some of the off-target effects we are still characterizing)
Typical dosing range: 200-1000 mcg subcutaneously, five nights on/two nights off, with initial dosing for females often starting at 0.1-0.3 mg daily and adjusted based on individual response and lab findings
A PubMed study shows that GLP-1 receptor agonists like Ozempic improve how your body uses insulin, lowering blood sugar levels both when fasting and after meals
Some users report mild headaches, particularly during the first few days of use
(PubMed) Qin B, Xun P, Jacobs DR, Jr., et al